<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>329</serviceExecutionTime><Drug id="49898"><DrugName>MPL-containing Pollinex allergy desensitization vaccine (weed), Allergy Therapeutics</DrugName><DrugNamesKey><Name id="42809002">Pollinex Quattro (weed allergy vaccine)</Name><Name id="42809001">Quattro MPL (weed allergy vaccine)</Name></DrugNamesKey><DrugSynonyms><Name><Value>Quattro MPL (weed allergy vaccine)</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Pollinex Quattro (weed allergy vaccine)</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>mugwort/plantain SC vaccines, Allergy Therapeutics</Value></Name><Name><Value>MPL-containing Pollinex allergy desensitization vaccine (weed), Allergy Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="25866">Allergy Therapeutics plc</CompanyOriginator><CompaniesPrimary><Company id="25866">Allergy Therapeutics plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1012939">AllerPharma Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1012939" type="Company"><TargetEntity id="5034972339" type="organizationId">Allerpharma Inc</TargetEntity></SourceEntity><SourceEntity id="25866" type="Company"><TargetEntity id="4295894147" type="organizationId">Allergy Therapeutics PLC</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Allergy - Germany - Sep-1999</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="12">Allergy</Indication></IndicationsPrimary><ActionsSecondary><Action id="386">Vaccine</Action><Action id="524">Adjuvant</Action></ActionsSecondary><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J7</Code><Name>VACCINES</Name></Ephmra></EphmraCodes><LastModificationDate>2016-02-17T15:18:09.000Z</LastModificationDate><ChangeDateLast>2012-03-27T05:00:44.000Z</ChangeDateLast><AddedDate>2004-05-06T11:17:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25866" linkType="Company"&gt;Allergy Therapeutics Ltd&lt;/ulink&gt; (ATL) has developed and launched an allergy desensitization vaccine against plantain and mugwort weed pollen (one of its Pollinex Quattro vaccines), consisting of a tyrosine-adsorbed glutaraldehyde-modified pollen allergen extract incorporating Corixa's monophosphoryl lipid A adjuvant (&lt;ulink linkID="8045" linkType="Drug"&gt;MPL adjuvant, Corixa&lt;/ulink&gt;) [&lt;ulink linkID="345061" linkType="reference"&gt;345061&lt;/ulink&gt;], [&lt;ulink linkID="536891" linkType="reference"&gt;536891&lt;/ulink&gt;]. In September 1999, this was one of several Pollinex Quattro vaccines launched in Germany on a named-patient basis [&lt;ulink linkID="345061" linkType="reference"&gt;345061&lt;/ulink&gt;], [&lt;ulink linkID="512945" linkType="reference"&gt;512945&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="1012939" linkType="Company"&gt;Allerpharma&lt;/ulink&gt; was investigating the drug  in Canada [&lt;ulink linkID="589549" linkType="Reference"&gt;589549&lt;/ulink&gt;]. In March 2012, development was ongoing [&lt;ulink linkID="1274325" linkType="Reference"&gt;1274325&lt;/ulink&gt;]; however, no recent development has been reported.&lt;/para&gt;&lt;para&gt;In September 1999,  the company was hoping to extend the registration program for these vaccines to further countries [&lt;ulink linkID="345061" linkType="reference"&gt;345061&lt;/ulink&gt;]; however, no further development has been reported for Pollinex Quattro vaccines against plantain and mugwort and, by February 2004, clinical trials did not appear to be ongoing to facilitate further registrations, unlike the ongoing European development for the grass and tree pollen vaccines [&lt;ulink linkID="533955" linkType="reference"&gt;533955&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In 2002, results were published of a post-marketing surveillance study of 1736 patients treated with Pollinex Quattro vaccine using patient-specific combinations of formulations against pollen from grasses, rye, trees, mugwort and plantain. The results showed that reduced medication was required by 62.2% of patients and reduced symptoms were found in 82.4%. There was a significant reduction in medication consumption (p=0.001). The vaccines were well tolerated and self-assessment of acceptability was rated as good or very good by 89.5% of patients [&lt;ulink linkID="536891" linkType="reference"&gt;536891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2003, results were published of a similar multicenter study of 1808 patients treated with Pollinex Quattro vaccine formulations made up to according to individual sensitivities, including against weed allergies. The patients were treated with a 3-injection initial course followed by a 3-injection maintenance course. The results showed efficacy of the vaccination, as demonstrated by a considerable decrease in regular and frequent use of medication compared with that in the previous season (p &amp;lt; 0.001). In addition, in 80% of the patients, the physician's assessment was either "good" or "very good". There was a low incidence of mainly mild adverse events [&lt;ulink linkID="536910" linkType="reference"&gt;536910&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The vaccines require a course of four injections that can be completed in as little as 3 weeks; other allergy desensitization treatments available in 1999, including the company's established range of Pollinex vaccines which do not incorporate MPL, involve a series of injections at weekly and then monthly intervals for up to 3 years [&lt;ulink linkID="301434" linkType="reference"&gt;301434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, Allerpharma acquired the Canadian rights to develop and market ATL's Pollinex-Quattro vaccines [&lt;ulink linkID="589549" linkType="Reference"&gt;589549&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ATL announced in October 1998 that it had acquired the rights to MPL from Ribi (now Corixa) for use in its allergy desensitization products [&lt;ulink linkID="301434" linkType="reference"&gt;301434&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25866">Allergy Therapeutics plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-09-30T00:00:00.000Z</StatusDate><Source id="345061" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1012939">AllerPharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1012939">AllerPharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-01-05T00:00:00.000Z</StatusDate><Source id="589549" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1012939">AllerPharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25866">Allergy Therapeutics plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="107703" title="AllerPharma to develop Allergy Therapeutic's Pollinex Quattro allergy vaccines in Canada  "></Deal><Deal id="124282" title="Allergy Therapeutics to license monophosphoryl lipid A adjuvant from Ribi"></Deal></Deals><PatentFamilies><PatentFamily id="498553" number="WO-09844947" title="Allergen formulation."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AllerPharma Inc" id="1012939"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergy Therapeutics plc" id="25866"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>